Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis

Annals of Surgery

Volumn 231, Issue 6, 2000, Pages 789-794

  Salartash, Khashayar ^a   Lepore, Michael ^a   Gonze, Mark D ^a   Leone Bay, Andrea ^b   Baughman, Robert ^b   Sternbergh III, W Charles ^a   Bowen, John C ^a   Money, Samuel R ^a,c  

^a OCHSNER MEDICAL CENTER   (United States)

^b Emisphere Technologies   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; SODIUM N [10 (2 HYDROXYBENZOYL)AMINO] DECANOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; COVALENT BOND; DEEP VEIN THROMBOSIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INDUCED DISEASE; GASTROSTOMY; INFERIOR CAVA VEIN; INTESTINE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENTERAL NUTRITION; EVALUATION STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; INTESTINAL ABSORPTION; RANDOM ALLOCATION; SWINE; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 0034038961     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200006000-00002     Document Type: Article

References (13)

1. Meissner MH, Strandness DE. Pathophysiology and natural history of acute deep venous thrombosis. In: Rutherford RB, ed. Vascular Surgery. Philadelphia: WB Saunders; 1999:1920-1937.
2. Crowther M, Hirsh J. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Semin Thromb Hemost 1997; 23:77-81.
3. Harrison L, Mc Ginnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-venous thrombosis with low molecular weight heparin. Arch Intern Med 1998; 158:2001-2003.
4. Innes GD, Dillon EC, Holmes A. Low-molecular-weight heparin in the emergency department treatment of venous thromboembolism. J Emerg Med 1997; 15:563-566.
5. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with home care injection. Arch Intern Med 1998; 158: 1809-1812.
6. Grau E, Real E, Pastor E, Viciano V, Aguilo J. Home treatment of deep vein thrombosis: a two-year experience at a single institution. Haematologica 1998; 83:438-441.
7. Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enoxaparin, a low-molecular-weight heparin, suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 1997; 86:349-354.
8. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-681.
9. Bounameaux H. Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism. Vasc Med 1998; 3:41-46.
10. Hosaka J, Roy S, Kvernebo K, Enge I, Laerum F. Induced thrombosis in the pig inferior vena cava: a model of deep venous thrombosis. J Vasc Interv Radiol 1996; 7:395-400.
11. Drug and Therapeutics Bulletin 1998; 36:25-29.
12. Salartash K, Gonze MD, Leone-Bay A, et al. Oral low-molecular-weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J Vasc Surg 1999; 30:526-532.
13. Litin SC, Heit JA, Mees KA. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. Mayo Clin Proc 1998; 73:545-550.